Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412845 | 0.95 | DRD2 (0.39) | MTNR1AMTNR1BCCR3DRD3DRD2 | |
| SCHEMBL5414913 | 0.95 | MTNR1A (0.41) | MTNR1AMTNR1BDRD3DRD2OPRD1 | |
| SCHEMBL5405069 | 0.91 | MTNR1A (0.38) | MTNR1AMTNR1BCCR3DRD3DRD2 | |
| SCHEMBL5420274 | 0.90 | DRD2 (0.42) | MTNR1AMTNR1BDRD3DRD2 | |
| SCHEMBL5409922 | 0.87 | CARM1 (0.36) | DRD2 | |
| SCHEMBL5425381 | 0.86 | CCR3 (0.38) | CCR3DRD3DRD2 | |
| SCHEMBL5412618 | 0.86 | MTNR1A (0.39) | MTNR1ACCR3DRD2OPRD1 | |
| SCHEMBL5428041 | 0.84 | MTNR1A (0.41) | MTNR1AMTNR1BCCR3 | |
| SCHEMBL5421294 | 0.84 | DRD2 (0.38) | CCR3DRD3DRD2 | |
| SCHEMBL5410797 | 0.84 | DRD3 (0.40) | DRD3DRD2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160894-B2 | Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-01-09 | — | — | US | claimed |
| EP-1632492-A1 | TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2006-03-08 | — | — | EP | claimed |
| US-20050096310-A1 | Tricyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096310-A1 | Tricyclic compound | MYLK3, CSNK1A1L, MYLK | MTNR1A 527/4885MTNR1B 731/4885CCR3 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.